Issue

Vol. 12 (2020)

One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy

https://doi.org/10.1007/s40820-020-00472-8
Chao Hong
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Jianming Liang
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Jiaxuan Xia
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Ying Zhu
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510006, People’s Republic of China
Yizhen Guo
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Anni Wang
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Chunyi Lu
School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People’s Republic of China
Hongwei Ren
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Chen Chen
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Shiyi Li
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Dan Wang
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China
Huaxing Zhan
Shanghai Ginposome Pharmatech Co., Ltd, Shanghai 201600, People’s Republic of China
Jianxin Wang
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People’s Republic of China

Corresponding Author: Jianxin Wang

jxwang@fudan.edu.cn

Nano-Micro Letters, Vol. 12 (2020), Article Number: 129

Abstract

Liposomes hold great potential in anti-cancer drug delivery and the targeting treatment of tumors. However, the clinical therapeutic efficacy of liposomes is still limited by the complexity of tumor microenvironment (TME) and the insufficient accumulation in tumor sites. Meanwhile, the application of cholesterol and polyethylene glycol (PEG), which are usually used to prolong the blood circulation and stabilize the structure of liposomes respectively, has been questioned due to various disadvantages. Herein, we developed a ginsenoside Rh2-based multifunctional liposome system (Rh2-lipo) to effectively address these challenges once for all. Different with the conventional ‘wooden’ liposomes, Rh2-lipo is a much more brilliant carrier with multiple functions. In Rh2-lipo, both cholesterol and PEG were substituted by Rh2, which works as membrane stabilizer, long-circulating stealther, active targeting ligand, and chemotherapy adjuvant at the same time. Firstly, Rh2 could keep the stability of liposomes and avoid the shortcomings caused by cholesterol. Secondly, Rh2-lipo showed a specifically prolonged circulation behavior in the blood. Thirdly, the accumulation of the liposomes in the tumor was significantly enhanced by the interaction of glucose transporter of tumor cells with Rh2. Fourth, Rh2-lipo could remodel the structure and reverse the immunosuppressive environment in TME. When tested in a 4T1 breast carcinoma xenograft model, the paclitaxel-loaded Rh2-lipo realized high efficient tumor growth suppression. Therefore, Rh2-lipo not only innovatively challenges the position of cholesterol as a liposome component, but also provides another innovative potential system with multiple functions for anti-cancer drug delivery.


Highlights:


1 A ginsenoside Rh2-based multifunctional liposome system (Rh2-lipo) was innovatively developed.
2 Rh2-lipo not only innovatively challenges the position of cholesterol as a liposome component, but also provides another innovative potential system with multiple functions for anti-cancer drug delivery.

Keywords

Ginsenoside Rh2 Liposomes Cholesterol Multifunction Tumor targeting
Hong, Chao, Jianming Liang, Jiaxuan Xia, Ying Zhu, Yizhen Guo, Anni Wang, Chunyi Lu, Hongwei Ren, Chen Chen, Shiyi Li, Dan Wang, Huaxing Zhan, and Jianxin Wang. 2020. “One Stone Four Birds: A Novel Liposomal Delivery System Multi-Functionalized With Ginsenoside Rh2 for Tumor Targeting Therapy”. Nano-Micro Letters 12 (June):129. https://doi.org/10.1007/s40820-020-00472-8.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. L. Johnson, A. Gunasekera, M. Douek, Applications of nanotechnology in cancer. Discov. Med. 9, 374 (2010). https://doi.org/10.3322/CA.2007.0003
  2. L. Sercombe, T. Veerati, F. Moheimani, S.Y. Wu, A.K. Sood, S. Hua, Advances and challenges of liposome assisted drug delivery. Front. Pharmacol. 6, 286 (2015). https://doi.org/10.3389/fphar.2015.00286
  3. E.O. Blenke, E. Mastrobattista, R.M. Schiffelers, Strategies for triggered drug release from tumor targeted liposomes. Expert. Opin. Drug Del. 10, 1399–1410 (2013). https://doi.org/10.1517/17425247.2013.805742
  4. M.K. Riaz, M.A. Riaz, X. Zhang, C.C. Lin, K.H. Wong et al., Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int. J. Mol. Sci. 19, 195 (2018). https://doi.org/10.3390/ijms19010195
  5. D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013). https://doi.org/10.1038/nm.3394
  6. Y.Q. Su, L.R. Wang, K.F. Liang, M.Y. Liu, X.R. Liu, Y.Z. Song, Y.H. Deng, The accelerated blood clearance phenomenon of pegylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin. Asian J. Pharm. Sci. 13, 44–53 (2018). https://doi.org/10.1016/j.ajps.2017.07.003
  7. J.J.F. Verhoef, T.J. Anchordoquy, Questioning the use of pegylation for drug delivery. Drug Deliv. Transl. Res. 3, 499–503 (2013). https://doi.org/10.1007/s13346-013-0176-5
  8. D. Rosenblum, N. Joshi, W. Tao, J.M. Karp, D. Peer, Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018). https://doi.org/10.1038/S41467-018-03705-Y
  9. S.M. Moghimi, I. Hamad, R. Bunger, T.L. Andresen, K. Jorgensen et al., Activation of the human complement system by cholesterol-rich and pegylated liposomes—modulation of cholesterol-rich liposome-mediated complement activation by elevated serum ldl and hdl levels. J. Liposome Res. 16, 167–174 (2006). https://doi.org/10.1080/08982100600848801
  10. J. Szebeni, L. Baranyi, S. Savay, M. Bodo, D.S. Morse et al., Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol-Heart C 279, H1319–H1328 (2000). https://doi.org/10.1152/ajpheart.2000.279.3.H1319
  11. D.S. Alberts, D.J. Garcia, Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54, 30–35 (1997). https://doi.org/10.2165/00003495-199700544-00007
  12. S. Marie, Liposomal and lipid-based formulations of amphotericin b. Leukemia 10, s93 (1996)
  13. S.J. Levine, T.J. Walsh, A. Martinez, P.Q. Eichacker, G. Lopez-Berestein, C. Natanson, Cardiopulmonary toxicity after liposomal amphotericin b infusion. Ann. Intern. Med. 114, 664 (1991). https://doi.org/10.7326/0003-4819-114-8-664
  14. O. Ringden, E. Andstrom, M. Remberger, B.M. Svahn, J. Tollemar, Allergic reactions and other rare side-effects of liposomal amphotericin. Lancet 344, 1156–1157 (1994). https://doi.org/10.1016/s0140-6736(94)90663-7
  15. K.M. Skubitz, A.P. Skubitz, Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (doxil). Anticancer Drugs 9, 45–50 (1998). https://doi.org/10.1097/00001813-199801000-00005
  16. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao et al., Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase i studies. J. Clin. Oncol. 13, 1777–1785 (1995). https://doi.org/10.1200/JCO.1995.13.7.1777
  17. F.H. O’Neill, T.A.B. Sanders, G.R. Thompson, Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies. Am. J. Cardiol. 96, 29–36 (2005). https://doi.org/10.1016/j.amjcard.2005.03.017
  18. J. Gallova, D. Uhrikova, N. Kucerka, M. Svorkova, S.S. Funari et al., Influence of cholesterol and beta-sitosterol on the structure of eypc bilayers. J. Membrane Biol. 243, 1 (2011). https://doi.org/10.1007/s00232-011-9387-1
  19. L.W. Qi, C.Z. Wang, C.S. Yuan, Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 72, 689–699 (2011). https://doi.org/10.1016/j.phytochem.2011.02.012
  20. K. Fukuda, H. Utsumi, J. Shoji, A. Hamada, Saponins can cause the agglutination of phospholipid-vesicles. Biochim. Biophys. Acta 820, 199–206 (1985). https://doi.org/10.1016/0005-2736(85)90113-0
  21. V.R. Akoev, R.E. Elemesov, B.S. Abdrasilov, Y.A. Kim, H.J. Park, Effects of triterpenoid glycosides of the dammaran series and their aglicons on phase transitions of dipalmitoylphosphatidylcholane. Biol. Membrany 13, 657–663 (1996)
  22. T. Yin, X.X. Cao, X.L. Liu, J. Wang, C.H. Shi et al., Interfacial molecular interactions based on the conformation recognition between the insoluble antitumor drug ad-1 and dspc. Colloid Surface B 146, 902–909 (2016). https://doi.org/10.1016/j.colsurfb.2016.07.040
  23. Y.Z. Wang, Q. Xu, W. Wu, Y. Liu, Y. Jiang, Q.Q. Cai, Q.Z. Lv, X.Y. Li, Brain transport profiles of ginsenoside rb1 by glucose transporter 1: in vitro and in vivo. Front. Pharmacol. 9, 398 (2018). https://doi.org/10.3389/fphar.2018.00398
  24. T.C. Chang, S.F. Huang, T.C. Yang, F.N. Chan, H.C. Lin, W.L. Chang, Effect of ginsenosides on glucose uptake in human caco-2 cells is mediated through altered na +/glucose cotransporter 1 expression. J. Agr. Food Chem. 55, 1993–1998 (2007). https://doi.org/10.1021/jf062714k
  25. R.A. Medina, G.I. Owen, Glucose transporters: expression, regulation and cancer. Biol. Res. 35, 9 (2002). https://doi.org/10.4067/s0716-97602002000100004
  26. S.H. Chen, Z.J. Wang, Y. Huang, S.A. O’Barr, R.A. Wong, S. Yeung, M.S.S. Chow, Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid-Based Compl. Alt. 2014, 168940 (2014). https://doi.org/10.1155/2014/168940
  27. Q. Lv, N. Rong, L.J. Liu, X.L. Xu, J.T. Liu, F.X. Jin, C.M. Wang, Antitumoral activity of (20R)- and (20S)-ginsenoside Rh2 on transplanted hepatocellular carcinoma in mice. Planta Med. 82, 705 (2016). https://doi.org/10.1055/s-0042-101764
  28. Y.J. Lin, Y. Li, Z.G. Song, H.Y. Zhu, Y.H. Jin, The interaction of serum albumin with ginsenoside Rh2 resulted in the downregulation of ginsenoside Rh2 cytotoxicity. J. Ginseng Res. 41, 330–338 (2017). https://doi.org/10.1016/j.jgr.2016.06.005
  29. W.W.G. Jia, X.X. Bu, D. Philips, H. Yan, G.Y. Liu, X.G. Chen, J. Bush, G. Li, Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can. J. Physiol. Pharm. 82, 431–437 (2004). https://doi.org/10.1139/Y04-049
  30. S. Han, A.J. Jeong, H. Yang, K. Bin Kang, H. Lee et al., Ginsenoside 20(s)-Rh2 exerts anti-cancer activity through targeting il-6-induced jak2/stat3 pathway in human colorectal cancer cells. J. Ethnopharmacol. 194, 83–90 (2016). https://doi.org/10.1016/j.jep.2016.08.039
  31. C.L. Zhu, F. Liu, W.B. Qian, T.Y. Zhang, F. Li, Combined effect of sodium selenite and ginsenoside rh2 on hct116 human colorectal carcinoma cells. Arch. Iran. Med. 19, 23 (2016)
  32. S.S. Hong, J.Y. Choi, J.O. Kim, M.K. Lee, S.H. Kim, S.J. Lim, Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation. Int. J. Nanomed. 2016, 4465–4477 (2016). https://doi.org/10.2147/Ijn.S113723
  33. S.Q. Xia, C. Tan, Y.T. Zhang, S. Abbas, B. Feng, X.M. Zhang, F. Qin, Modulating effect of lipid bilayer-carotenoid interactions on the property of liposome encapsulation. Colloid Surface B 128, 172–180 (2015). https://doi.org/10.1016/j.colsurfb.2015.02.004
  34. C.M.J. Hu, L. Zhang, S. Aryal, C. Cheung, R.H. Fang, L.F. Zhang, Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 108, 10980–10985 (2011). https://doi.org/10.1073/pnas.1106634108
  35. S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz et al., Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781 (2013). https://doi.org/10.1038/nnano.2013.181
  36. A.L. Barran-Berdon, D. Pozzi, G. Caracciolo, A.L. Capriotti, G. Caruso et al., Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29, 6485–6494 (2013). https://doi.org/10.1021/la401192x
  37. M. Mahmoudi, A.M. Abdelmonem, S. Behzadi, J.H. Clement, S. Dutz et al., Temperature: the “ignored” factor at the nanobio interface. ACS Nano 7, 6555–6562 (2013). https://doi.org/10.1021/nn305337c
  38. W.K. Subczynski, J. Widomska, J.B. Feix, Physical properties of lipid bilayers from epr spin labeling and their influence on chemical reactions in a membrane environment. Free Radical. Bio. Med. 46, 707–718 (2009). https://doi.org/10.1016/j.freeradbiomed.2008.11.024
  39. C. MacDermaid, M. Klein, G. Fiorin, Molecular dynamics simulations of cholesterol-rich membranes using a coarse-grained force field for cyclic alkanes. J. Chem. Phys. 143, 243144 (2015). https://doi.org/10.1063/1.4937153
  40. J.J. Inbaraj, T.B. Cardon, M. Laryukhin, S.M. Grosser, G.A. Lorigan, Determining the topology of integral membrane peptides using EPR spectroscopy. J. Am. Chem. Soc. 128, 9549–9554 (2006). https://doi.org/10.1021/ja0622204
  41. Z.E. Suntres, Liposomal antioxidants for protection against oxidant-induced damage. J. Toxicol. 2011, 152474 (2011). https://doi.org/10.1155/2011/152474
  42. Y.C. Chen, R. Xia, Y.X. Huang, W.C. Zhao, J. Li et al., An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun. 7, 13443 (2016). https://doi.org/10.1038/Ncomms13443
  43. S. Jain, D. Kumar, N.K. Swarnakar, K. Thanki, Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33, 6758–6768 (2012). https://doi.org/10.1016/j.biomaterials.2012.05.026
  44. X.L. Sun, X.F. Yan, O. Jacobson, W.J. Sun, Z.T. Wang et al., Improved tumor uptake by optimizing liposome based res blockade strategy. Theranostics 7, 319–328 (2017). https://doi.org/10.7150/thno.18078
  45. M. Papi, D. Caputo, V. Palmieri, R. Coppola, S. Palchetti et al., Clinically approved pegylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells. Nanoscale 9, 10327–10334 (2017). https://doi.org/10.1039/c7nr03042h
  46. A. Bigdeli, S. Palchetti, D. Pozzi, M.R. Hormozi-Nezhad, F.B. Bombelli, G. Caracciolo, M. Mahmoudi, Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10, 3723–3737 (2016). https://doi.org/10.1021/acsnano.6b00261
  47. S.D. Li, L. Huang, Stealth nanoparticles: high density but sheddable peg is a key for tumor targeting. J. Control. Release 145, 178–181 (2010). https://doi.org/10.1016/j.jconrel.2010.03.016
  48. N. Bertrand, P. Grenier, M. Mahmoudi, E.M. Lima, E.A. Appel et al., Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat. Commun. 8, 777 (2017). https://doi.org/10.1038/s41467-017-00600-w
  49. S. Schottler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailander, F.R. Wurm, Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat. Nanotechnol. 11, 372–377 (2016). https://doi.org/10.1038/Nnano.2015.330
  50. L. Miao, C.M. Lin, L. Huang, Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J. Control. Release 219, 192–204 (2015). https://doi.org/10.1016/j.jconrel.2015.08.017
  51. Y. Chen, Q. Yu, C.B. Xu, A convenient method for quantifying collagen fibers in atherosclerotic lesions by imagej software. Int. J. Clin. Exp. Med. 10, 14904–14910 (2017)
  52. D.J. Verbik, S.S. Joshi, Immune cells and cytokines—their role in cancer-immunotherapy (review). Int. J. Oncol. 7, 205–223 (1995). https://doi.org/10.3892/ijo.7.2.205
Read More
Author biographies are not available.
Download this PDF file
PDF SUPPLEMENTARY MATERIAL
Statistic
Read Counter : 6087 Download : 4604

Most read articles by the same author(s)

1 2 > >>